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Abstract
How cells coordinate the immune system activities is important for potentially life-saving organ or stem
cell transplantations. Polymorphic immunoregulatory genes, many of them located in the human major
histocompatibility complex, impact the process and assure the proper execution of tolerance-versus-
activity mechanisms. In haematopoietic stem cell transplantation, on the basis of fully human leukocyte
antigen (HLA)-matched donor–recipient pairs, adverse effects like graft versus leukaemia and graft versus
host are observed and difﬁcult to handle. So far, high-resolution HLA typing was performed with Sanger
sequencing, but for methodological reasons information on additional immunocompetent major histo-
compatibility complex loci has not been revealed. Now, we have used microarray sequence capture and
targeted enrichment combined with next generation pyrosequencing for 3.5 million base pair human
major histocompatibility complex resequencing in a clinical transplant setting and describe 3025
variant single nucleotide polymorphisms, insertions and deletions among recipient and donor in a
single sequencing experiment. Taken together, the presented data show that sequence capture and mas-
sively parallel pyrosequencing can be used as a new tool for risk assessment in the setting of allogeneic
stem cell transplantation.
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1. Introduction
Haematopoietic stem cell transplantation (HSCT) is
a well-established treatment in various haematologic
malignancies. Advances in clinical practice and
improvements in donor–patient matching have
produced signiﬁcant better outcomes in related and
unrelated allogeneic HSCT. Especially, reﬁnements in
high-resolution DNA-based tissue typing and knowl-
edge which transplantation antigens are most signiﬁ-
cant when selecting donors for recipients helped to
improve and prolong survival rates.
1 The classical
transplantation antigens deﬁned as human leukocyte
antigens (HLA) are physically located within a 4M b
highly polymorphic multigene region, known as the † These authors contributed equally to this work.
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some 6.
2–4 Many of the genes annotated inside the
MHC have immune-related functions, for instance
genes involved in HLA expression and transport or
antigen degradation and presentation. Hence, MHC-
located genes with distinct extensive polymorphisms
play a fundamental role in transplantation medicine
and moreover in autoimmune, inﬂammatory and
infection diseases in humans.
5,6
From the clinical perspective, exact HLA typing for
class I and class II genes is a necessity for haematologic
stem cell transplantation.
7,8 In addition to HLA,
MHC-resident unidentiﬁed transplantation determi-
nants recently were proposed to be responsible for
graft-versus-host disease (GVHD).
9 Petersdorf et al.
identiﬁed signiﬁcantly increased risks of severe acute
GVHD and lower incidence of disease recurrence in
haplotype-mismatched HLA-matched unrelated
HSCT. Extended haplotypes of unrelated donors and
recipients were allusively deﬁned by applying a
mapping approach using the physical linkage of HLA-
A, -B and -DRB1. Another methodological approach,
measuring risks associated with donor–recipient
MHC microsatellite marker matches or mismatches,
showed increased or decreased risk for death and
GVHD development.
10
In case of yet unknown transplantation determi-
nants located inside the MHC region, new technol-
ogies are essential for providing direct insights.
Current approaches to deﬁne MHC-resident disease
association are generally based on analytical
methods for indirect haplotype determination.
Deﬁnition of haplotype blocks
11 with linked dedi-
cated genetic variants is an effective tool, however
phasing of long-distance segments is required and
comes with several challenging issues and systemic
limitations.
11 Due to the long genetic distances
between MHC loci and the necessity for phasing of
uneven distributed single nucleotide polymorphisms
(SNPs), long-range haplotyping is hard to achieve.
Now, we hypothesize that applying targeted
sequence capture to the human MHC, ideally com-
bined and enhanced by HLA typing
12–14 in one
single diagnostic sequencing experiment, provides
additional information on transplant outcome.
Here we describe for the ﬁrst time NimbleGen
sequence capture on solid surface for targeted MHC
resequencing by 454 sequencing in a clinical trans-
plant setting. Moreover, to address the accuracy of
the sequencing approach, we analysed approximately
1500 SNP markers mapping along the sequenced
MHC region using genome-wide SNP arrays. For this
study, we selected a patient who underwent unrelated
HLA-matched allogeneic stem cell transplantation,
the fully matched unrelated donor and also the
parents of the patient. The patient developed acute
GVHD after transplantation and died 1.5 months
later.
Thus, we show that MHC resequencing, although
applied to two HLA-identical genomes, reveals a
large number of genetic differences and variants
potentially linked to GVHD development. Various
differences causing non-synonymous amino acid
exchanges are discussed for their inﬂuence on GVHD
development or drug efﬁcacy and donor selection.
In contrast to microarray-based SNP analysis or haplo-
type association studies, direct resequencing offers the
near-complete information on genotypic differences
for important transplantation outcome determinants
at the single nucleotide resolution level.
2. Material and methods
2.1 Clinical setting and experimental design
We performed a comprehensive MHC resequencing
approach and analysed a patient with acute myeloid
leukaemia undergoing HLA-matched allergenic HSCT,
the unmatched donor and the patient’s parents.
Initial donor selection was performed using molecular
high-resolution HLA typing by Sanger sequencing.
Written consent was obtained from all patients and
donors as required by the institutional review board
in accordance with the Declaration of Helsinki. The
transplant was matched for 10 out of 10 alleles. The
patient underwent a myeloablative busulfan/cyclo-
phosphamide-basedconditioningregimebeforetrans-
plantation. Short-course methotrexate combined with
mycophenolate mofetil was used as a standard GVHD
prophylaxis, due to intolerance to calcineurin inhibi-
tors. On Day þ21 after transplantation the patient
developed acute GVHD Grade IV (skin IV, liver IV, gut
II; Seattle criteria) and died 3 weeks later.
After microarray sequence capture and enrichment
(SCE), MHC-targeted resequencing of 3.5 million
base pairs for all four DNA samples was performed
on a single Genome Sequencer instrument run.
Additionally, microarray based genome-wide SNP
analysis (Affymetrix Genome-wide Human SNP Nsp/
Sty 6.0) was performed for donor and recipient for
further MHC and genome-wide SNP analysis.
2.2 DNA samples
GenomicDNAwasisolatedandpuriﬁed fromvenous
blood samples using the magnetic bead extracting
MagNaPure Compact instrument (Roche Diagnostics,
Mannheim, Germany) following the manufactu-
rer’s instructions. DNA concentration and quality
were photometrically determined (BioPhotometer,
Eppendorf, Hamburg, Germany).
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The samples were typed initially for loci A, C, DQB1
and DRB1 using a commercial typing kit (S4 HLA-
DRB1 and S3 HLA-A/C/DQB1; Protrans, Hockenheim,
Germany) and HLA-B (AlleleSEQR HLA-B; Atria
Genetics, South San Francisco, CA). PCR products were
treated with ExoSAP-iT (Amersham Biosciences,
Freiburg, Germany) to remove primers and dNTPs and
puriﬁed by size exclusion chromatography with
Sephadex
w G-50 (Sigma-Aldrich, Steinheim,
Germany). Direct cycle sequencing was performed in
a 9800 Fast Thermal Cycler (Applied Biosystems,
Foster City, CA) using the BigDyeTerminatorTM v1.1
chemistry (Applied Biosystems) with the respective
sequencing primers. The sequencing platform was
an ABI Prism 3100 Genetic Analyzer (Applied
Biosystems). The sequences representing frequent and
well-knownalleleswereanalysedbytheAssign3.5soft-
ware (Conexio Genomics) and presented in Table 1.
2.4 Affymetrix genome-wide SNP analysis
For genome-wide SNP determination, an Affymetrix
Genome-wide Human SNP Array (Nsp/Sty Assay Kit
5.0/6.0; carrying 909,622 SNP markers) processing
with sample preparation, digestion, ligation, ampliﬁ-
cation, labelling, hybridization, staining and scanning
were conducted according to the manufacturer’s
instructions. For donor and recipient, 250 ng of
double-stranded genomic DNA starting material
were digested with Nsp I and Sty I (New England
BioLabs GmbH, Frankfurt, Germany). Hybridizations
were conducted with one replicate of all times and
treatments concurrently. Each array image was visu-
ally screened to count for general signal quality and
then submitted to Genotyping Console 4.0
(Affymetrix). Genotype calling was determined by
the Birdseed version 2.0 using 90 HapMap reference
samples for cluster analysis.
2.5 Sequence capture and enrichment
Design and production of a GS FLX Titanium opti-
mized sequence capture array (385k) was done at
NimbleGen(RocheNimbleGen,Madison,WI)targeting
5 Mb reference sequence (human hg18) spanning
the MHC complex on chromosome 6 (NCBI: chr6 NGS
primary_target_region 29,594,756-33,046,546).
Targeted sequence capture, with pre-capture ligation-
mediated PCR (LM-PCR), hybridization, washing,
elution and quantitative PCR (qPCR) to assess capture
success, was performed according to the manufac-
turer’s instructions. According to ENSEMBL v49
release (HG 18 in UCSC nomenclature) reference
genome, the ﬁnal target bases covering the complete
MHC class I, II and III regions were deﬁned to be
3 451 791 bp; of those 2 922 962, target bases
(84.7%) were covered by capture oligonucleotides as
deﬁnedbyNimbleGensdefaultsettingsforprobeselec-
tion. 528 829 bp (15.3%) of the initial target region
were omitted due to reasons of speciﬁcity and
uniqueness.
2.6 MHC genotyping by Roche/454 Genome
Sequencer FLX sequencing
Using the titanium-optimized sequence, capture
protocol provides the captured DNA ready for use in
454 emPCR because required adaptor sequences are
integrated during the LM-PCR step. The four captured
DNA-sequencing libraries were prepared separately
and each one loaded on one of the four-lane gasket
PicoTiterPlate device (PTP; 70 75 mm; Roche/454),
respectively. Each library was quantitated by Pico-
Green
w (Quant-iTTM, Molecular Probes, Invitrogen),
diluted to 1   10
5 molecules/ml and used for
emPCR at a ratio of 0.1 copies of library fragments
per DNA capture bead. After the DNA capture bead
recovery, DNA capture bead enrichment, to separate
DNA-carrying beads from non-DNA carrying beads,
was performed. Finally, we loaded 490 000–
690 000 then single-strand DNA carrying beads on
the PTP. The sequencing itself was performed on a
Genome Sequencer FLX system using titanium chem-
istry and standard Roche 454 protocols (Lib-L SV; Rev.
Jan 2010). Sequence information is available on NCBI
(release on 2011-11-24; Accession nb: SRP004546).
2.7 Data analysis
2.7.1 Image processing to gene annotation Image
processing and base calling was performed with GS
FLX software (Roche/454 Life Sciences). For 100%
identity contiguous sequence production, the GS
Reference Mapper (Roche/454 Life Sciences) was
Table 1. HLA typing results
Parent 1 Parent 2
A* 29 01 A* 02 32
B* 44 57 B* 44 14
C* 06 06 C* 05 08
DRB1* 03 07 DRB1* 04 07
DQB1* 03 03 DQB1* 03 02
DPB1* 04 04 DPB1* 04 04
Recipient Donor
A* 01:01 02:01 A* 01:01 02:01
B* 57:01 44:02 B* 57:01 44:02
C* 06:02 05:01 C* 06:02 05:01
DRB1* 07:01 04:01 DRB1* 07:01 04:01
DQB1* 03:03 03:02 DQB1* 03:03 03:02
DPB1* 04:01 04:01 DPB1* 04:01 04:01
*DNA based typing.
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eight MHC haplotypes provided a comprehensive
reference sequence database, which is consequently
used for variation assessments in the present study
4.
Haplotype (A3-B7-DR15) of the cell line PGF was
designated as the new MHC reference sequence,
representing the reference sequence for the used
capture oligonucleotide design (NCBI human HG
18). Genes were annotated according to the
Vertebrate Genome Annotation database (http://
www.VEGA.sanger.ac.uk) on the basis of the refer-
enced PGF cell line.
2.7.2 Gene annotation to variant analysis A series
of Perl scripts was developed and applied to deter-
mine the type (substitute, insertion, deletion, synon-
ymous or non-synonymous) and quantity (number
of reads per variant) of variation between the four
samples and the reference cell line and in between
donor and recipient. A simple, but clear-cut ratio of
the number of matched or mismatched variants in
relation to the total number of sequenced base pairs
deﬁnes the similarity of actual or potential donor
and recipient MHC, reliably enabling fast qualiﬁcation
of possible donor-recipient matches with a single
quality factor over and above the obligatory HLA
match.
2.8 Variant analysis to graft-versus-host or disease
susceptibility
Additional series of Perl scripts allow to search and
compare for known disease associations or other
valued medical information. Parameters such as inter-
genic, intronic, coding/non-coding, synonymous/
non-synonymous and coverage as well as prevalence
are used to deﬁne a list of SNPs to start batch analysis
in NCBI’s OMIM or related databases. Once the
sequence data were generated by the sequencing
instrument, it took just 2 h for the data analysis pro-
grams to analyse the raw data and generate report
variation and disease association information. A
summary table with all prominent types of SNPs in
resequenced regions with at least 20-fold coverage is
presented in Table 2.
3. Results and Discussion
3.1 Efﬁciency of the enrichment process
When estimating the efﬁciency of the enrichment
process, the four different probes (NSC0237,
NSC0247, NSC0268 and NSC0272) included in the
sequence capture assay were quantiﬁed by qPCR
before and after the enrichment process revealing
that 337-fold enrichment was achieved (ranging
from 164- to 851-fold). This is clearly above the
quality standard of 100-fold enrichment, which
should be realized when using microarray-based
sequence capture systems.
3.2 Speciﬁcity of the enrichment process
According to PGF reference alignment observations,
a total of 706 431 reads representing 78% of the
908 152 high-quality reads produced were located
Table 2. MHC resequencing: summary of insertions, deletions and mismatches for Parents 1 and 2, donor and recipient compared with
the reference cell line PGF
3.5 Mb human MHC resequencing
Parent 1 Parent 2 Donor Recipient Sum (%)
Exon
Insertion 18 28 28 23 97 (5.0)
Deletion 4 4 3 3 14 (0.7)
Mismatch 548 518 459 316 1841 (94.3)
Sum (%) 570 (10.2) 550 (13.3) 490 (10.2) 342 (7.3) 1952 (100)
Intron
Insertion 122 95 110 107 434 (7.3)
Deletion 16 12 11 14 53 (0.9)
Mismatch 1664 1109 1406 1278 5457 (91.8)
Sum (%) 1802 (32.3) 1216 (29.4) 1527 (31.9) 1399 (30.1) 5944 (100)
Intergenic
Insertion 138 134 137 152 561 (5.0)
Deletion 17 14 22 26 79 (0.7)
Mismatch 3050 2225 2605 2740 10 620 (94.3)
Sum (%) 3205 (57.5) 2373 (57.3) 2764 (57.8) 2918 (62.6) 11 260 (100)
Total 5577 4139 4781 4659
204 Human MHC Resequencing [Vol. 18,inside the speciﬁed MHC target region. 61 455 reads
(8.7%) were rejected due to length (,50 b), repeti-
tive or chimeric characteristics.
3.3 454 pyrosequencing
Libraries 1–4 (MHC Parent 1, MHC Parent 2, MHC
donor, MHC recipient) showed a post-emPCR and
recovery enrichment efﬁciency of 2.5, 4.5, 5.7 and
5.8%. As a consequence 490 450, 544 500,
682 950 and 690 900 DNA-capture beads per lane
were loaded to the GS-PTP (PicoTiterPlate) regions
1–4. The number of individual read sequences which
passed internal quality control ﬁlters, with a mean
read length of 350 bp, were 223 005, 225 385,
226 501 and 234 017, respectively, for each region.
3.4 MHC-resequencing coverage
In total, we were able to annotate 273 genes to our
MHC sequence data. For samples 1–4 (Parent 1,
Parent 2, donor and recipient) 165 956, 167 376,
178 588 and 194 511 reads were MHC matched
(Table 3). For contig analysis (parameters: 90% hom-
ology; three reads minimum for base pair position), a
sum of 1246 (3 009 032 bp, 87% of target), 1287
(2 931 090 bp, 85% of target), 1073 (3 036 931 bp
(88% of target) and 1129 (3 048 429 bp, 88% of
target) contigs with on average 140, 131, 174 and
179 reads per contig were generated. In total, 4735
contigs with 12 025 482 bp and 706 431 reads
were submitted for further analysis. On average, 13%
of the targeted 3.5 Mb MHC were missed by this rese-
quencing approach. For an annotated gene list of 273
genes (pseudogenes included) from the telomeric
gene DAQB-12N14.5 (MHC-extended class I) to the
centromeric gene BRD2 (MHC-class II) for which we
have full sequence, the coverage is on average 17-,
18-, 19- and 20-folds for each position for Parent 1,
Parent 2, donor and recipient, respectively (Table 3
and Fig. 1).
3.5 MHC-resequencing variation analysis
When comparing the sequence data of the four
individual MHC regions to PGF, a signiﬁcant number
of known (dbSNP included) and new (non-dbSNP
included) variant positions were detected. For parent
1 5 577, for parent 2 4139, for donor 4781 and
for the bone marrow transplanted patient 4659,
variant positions were detected. Among these 6%
are insertions, 1% are deletions and 93% represent
substitutions. An estimated 10% of all detected var-
iants afﬁliate to exonic, 31% to intronic and 59% to
intergenic regions. The complete numbers are
shown in Table 1.
Comparing the MHC sequences of donor and recipi-
ent with the reference PGF cell line, in sum 32 586
variant positions were detected with a 3-fold cover-
age. Analysing donor and recipient sequences directly
to each other, with the restriction to 10- or 20-fold
coverage these numbers drop to 15 699 and 4596,
respectively. Taking the mean of 3-, 10- and 20-fold
coverage numbers, these variant positions are
equally distributed and located 59% to intergenic,
7% to exonic and 34% to intronic regions.
Now, in the case of comparing the MHC sequences
of donor and recipient directly to each other, 3025
different positions were observed with coverage
greater or equal to 20-fold. Additional 1517 positions
are shared among donor and recipient, but differ with
PGF sequences. Comparing Parent 1 to recipient,
3639 variant positions differ. Comparing parent 2
and recipient showed 5790 differences. Analogous,
1574 and 2276 positions shared differ in comparison
to the referenced cell line. Figure 2 shows the graphi-
cal interpretation of similarities and dissimilarities
among possible donor and recipient genotypes.
Although, being far from perfect, donor versus recipi-
ent correlation compared with recipient versus parent
correlation show the inﬂuence of the HLA match.
Ultra-deep sequencing would be necessary to bring
Table 3. Summary of 454 MHC resequencing data after sequence capture microarray enrichment for parents, donor and recipient
3.5 Mb human MHC resequencing
454 genome
sequencer
1  instrument run
(titanium chemistry)
Contigs
(n)
a
Reads (n)
passed ﬁlter (%)
Reads (n)p .
Contig (n)
Coverage read
length (bp)
MHC
covered (%)
b
MHC not
covered (%)
b
Region 1 Parent 1 1246 174 382 (66%) 140 17  (342) 3 009 032 (87%) 438 685 (13%)
Region 2 Parent 2 1287 175 749 (66%) 137 18  (347) 2 931 090 (85%) 518 853 (15%)
Region 3 Donor 1073 186 819 (58%) 174 19  (352) 3 036 931 (88%) 410 878 (12%)
Region 4 Recipient 1129 202 358 (62%) 179 20  (340) 3 048 429 (88%) 400 206 (12%)
Sum 4735 739 311 12 025 485 1 768 (623)
Mean 1184 184 827 (63%) 157 18.5  (345) 3 006 371 (87%) 442 156 (13%)
aContigs match parameter: 90% homology, minimum three reads for a given position.
bPer cent of complete target length 3 451 791 bp.
No. 4] J. Pro ¨ll et al. 205the data closer to the homogenous or heterogenous
distribution values (50, 100%).
Analysis of the variant list with equal or greater than
20  coverage in donor and recipient showed, that
1492 are located in intergenic regions, 1173 in intro-
nic regions and 360 in exons. These 360 exon var-
iants represent, with 6.6 variant positions per gene,
a list of 59 genes (Fig. 3).
3.6 Variation analysis SNP microarray
SNP microarray variants (Affymetrix) with at least
10-fold coverage for recipient and donor with 1345
and 1382 SNPs show that 93.38% (n ¼ 1,256) for
recipient and 94.07% (n ¼ 1,300) for donor are vali-
dated by GS-FLX data, or vice versa. SNPs with no cov-
erage with GS-FLX data represent 1.3%, meaning, that
only 1.3% fall in gap regions, a value acceptable to be
Figure 1. MHC resequencing results for parents, donor and recipient compared with annotated gene loci. Graphs are representing at least 3-
fold coverage (present ¼ 1) or gaps (absent ¼ 0) for the complete 3.5 Mb spanning MHC region of the four sequenced DNA samples (P1,
parent 1), (P2, parent 2), (D, donor) and (R, recipient). Gaps present in P1 to R are a consequence of repeat rich regions and poor sequence
capture or failed ampliﬁcation. Graph for reference cell line PGF show known annotated gene loci in black (gene annotation ¼ 1).
Figure 2. MHC resequencing results. Variant correlation of parents, donor and recipient. (A–C) Correlating all detected variant positions in
percentage of reads per position for two individuals visualize the degree of sequence match. A clear reduction of variant positions is
desplayed in (C). (D) Cumulative coverage in percentage of target bases (blue p1, green p2, lila donor, red recipient).
206 Human MHC Resequencing [Vol. 18,low. Among those SNPs which differ with PGF, 46% are
heterozygous and 54% are homozygous. Data for
SNPs outside MHC comprise 885 576 speciﬁed
SNPs; among these, 551 954 (62.33%) are concor-
dant between donor and recipient. In contrast inside
MHC, 1365 (86.6%) SNPs match.
Taken together, here we report the performance of
newly developed methods for human MHC locus rese-
quencing, namely targeted microarray-mediated SCE
by NimbleGen and massively-parallel clonal pyrose-
quencing with 454’s next generation sequencing
technology. The genomes we partly resequenced rep-
resent a typical HSCT situation with 10 out of 10 HLA-
loci matched. The procedures we used were tested
with respect to efﬁciency and speciﬁcity of on-
surface sequence capture, and the ability to discover
genetic variation in coding and non-coding regions
comparing the genotypes with single-base resolution
for selected 3.5 Mb MHC sequence. In total, four
MHC captures from four different samples were per-
formed using DNA extracted from peripheral blood,
prepared for 454 sequencing separately and sub-
jected to one of the four sequencing regions on a
single picotitre plate. The intention of the study was
not to look at known or unknown GVHD-determining
parameters, but to show whether available technol-
ogies and analytical software were powerful enough
to start considering a study that addressed this
problem comprehensively.
3.7 Enrichment, sequencing and recipient-donor
pairing
In total, a mean of 337-fold enrichment achieved,
among these sequences 83% could be adjusted to
the targeted MHC sequences. We qualiﬁed both
values (enrichment and speciﬁcity) highly sufﬁcient
for sound comparison of sequence among samples.
454-pyrosequencing gave approximately und genau?
200 000 reads per sample. A mean of 87% of the
MHC was resequenced with at least 3-fold coverage.
The MHC-resequencing variation analysis we chose
resulted in a simple but clear score for comparing
genotype variants. When comparing two individuals
on the genotype level, we, ﬁrst, describe and second,
simply count the numbers of single nucleotide
variant positions, including insertions or deletions
neglecting any known functional background and
score a simple number to each possible transplant-
pair donor versus recipient 3025, Parent 1 versus reci-
pient 3696 and Parent 2 versus recipient 5790.
Applying this type of analysis can reveal the best ﬁt
donor out from a series of equally well fully HLA-
matched candidates. As already mentioned, we
cannot yet discriminate between expected transplant
outcome, but we can analyse each MHC with single
nucleotide resolution what can help with dependence
on known disease association or possible immunolo-
gic activity generating as well as drug-acceptance
potential for each and any SNP to select the best-
suited donor candidate.
3.8 Genes and SNPs
On the basis of this individual MHC resequencing
data and gene annotation, all database including
genetic variant information for a total of 273 genes
was gathered. To date numerous SNPs are described
for these regions. Among these, all variants located in
exons of the 45 MHC resident genes with known
immunologic function, presented in Supplementary
data only, show that a huge amount of possible
Figure 3. MHC resequencing results. Summary of variant positions between parents, donor and recipient.
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sibleforinﬂammationinductionwhenencounteredby
immunologic competent cells not tolerant against
them. In total, we have 30 protein-coding genes with
56 non-synonymous (44%) and 71 synonymous
(56%) sequence variants in exonic regions, three
RNA genes (HCG17, HCG27 and NCRNA00171)
and one transposable element (TIGD1L). Genes with
non-synonymous amino acid exchanges are
TUBB, GNL1, PRR3, HCG17, MDC1, HCG27, UBD,
PSMB9, HSPA1L, TAP2, PPP1R10, MSH5, CLIC, CFB,
C6orf10, TRIM40, CSNK2B, C6orf136 and BAT3. The
list of protein-coding genes with synonymous amino
acid exchanges, includes the genes PPP1R11, TRIM10,
MICB, C6orf205, TRIM26, TCF19, ZFP57, NEU1,
KIAA1949,GABBR1,DDR1,C6orf26andAIF1(Table4).
The gene most affected by sequence variation is
Tubulin beta. It is different in 54 positions in all four
exonic regions including 5 insertions (GG, T, TAAGA,
AA and TG) and 3 deletions (A, TG and T) with all var-
iants .22-fold coverage, among those positions
different 33 distinct variants result in 21 synonymous
amino acid changes. The data need further veriﬁca-
tion with additional bioinformatic tools with the
purpose to discriminate among tubulin family
members and true variants. But, tubulin beta func-
tions in microtubule formation and is therefore
important for many aspects of cell activity, including
morphogenesis, intracellular vesicle/signal transport
and cell cycle regulation. In breast cancer, tubulin-
associated SNPs are known to be responsible for
taxol/taxane resistance.
15 Another aspect of tubulin-
drug interaction is that beside taxane, noscapine, its
analoga and colchicine have tubulin-binding proper-
ties and inﬂuence anti-inﬂammatory activity by inhi-
bition of cytokine and chemokine release from
macrophages. Consequently, if tubulin-variant depen-
dent microtubule dynamics inﬂuence cytosolic signal-
ling, thus dampening inﬂammatory responses the
described individual differences might possibly help
explain why GVHD signals originate and sprout.
16 In
that context it is interesting to mention that GVHD
often starts in skin, gastrointestinal tract or liver and
that tubulin is involved in pathogenic Escherichia coli
infections, which cause inﬂammation and sepsis,
therefore it should be allowed to think, that tubulin
variants can contribute to GVHD in one or the other
way.
17,18
TIGD1L (tigger transposable element derived 1-like)
is a DNA transposon, or class 2 transposable element,
has also 17 genomic variants between recipient and
donor—meaning full or not? Generally spoken, the
inﬂuence of this class of elements on mammalian
genome evolution is very interesting and it would be
helpful to better understand their inﬂuence on the
immune system and why some species/individuals
are more susceptible to invasion by parasites or princi-
pal stress situations than others.
19
The next gene with high amounts of SNP differences
inourspeciﬁcrecipientanddonorsettingarethegenes
for the inhibitory units 11 and 10 of protein phospha-
tase 1 (PPP1R11; protein phosphatase 1, regulatory
(inhibitor) subunit 11 with 9 synonymous exchanges;
PPP1R10 1 non-synonymous and 1 synonymous
amino acid exchange). Especially, in combination with
CsA, most immunosuppressive drugs that support suc-
cessful allograft survival act by inhibiting or depleting T
lymphocytes by inhibiting protein phosphatases.
20
Another gene with two non-synonymous, ﬁve
synonymous amino acid exchange differences
between recipient and donor is the gene guanine
nucleotide-binding protein-like 1 (GNL1). Recently,
guanine nucleotide binding protein-like 3-like
(GNL3L), another member of the GNL family was
described to bind TRF1 (telomeric repeat-binding
factor 1). In addition to GNL, TRF1 can be bound
and modulated also by two nucleolar GTP-binding
proteins, nucleostemin, which exhibit apparently
opposite effects on the protein degradation of TRF1.
In particular, in a recent paper from Zhu et al.,
GNL3L is able to stabilize TRF1 protein during
mitosis and promote the metaphase-to-anaphase
transition.
21 Telomeric repeat binding factor 1
(TRF1) is a component of the multiprotein complex
‘shelterin’, which organizes the telomere into a high-
order structure.
TRIM10, TRIM 26, TRIM 40 have 4, 2 and 1 SNPs
differentwith1non-synonymousaminoacidexchange
in TRIM 40. A study using a cDNA expression screening
procedure in a patient–donor model with full HLA
match, the major target antigen of donor lymphocytes
was identiﬁed to be TRIM22-442 C, a polymorphic
allele of the tripartite motif family member TRIM22
(synonym: STAF50). The authors described that an
arginine(R)-to-cysteine(C) exchange at position 442
generated an immunogenic T cell epitope equivalent
to a minor histocompatibility antigen (mHag).
Approximately 1.3% of Caucasians carry TRIM22-442
C in association with HLA-A*02:01.
22
MICB, with only four synonymous exchanges
encodes a heavily glycosylated protein, which is a
Table 4. List of genes with variant positions
a between donor and
recipient
Non-synonymous amino acid changes: TUBB, GNL1, PRR3, HCG17,
MDC1, HCG27, UBD, PSMB9, HSPA1L, TAP2, PPP1R10, MSH5, CLIC,
CFB, C6orf10, TRIM40, CSNK2B, C6orf136 and BAT3
Synonymous amino acid changes: PPP1R11, TRIM10, MICB,
C6orf205, TRIM26, TCF19, ZFP57, NEU1, KIAA1949, GABBR1,
DDR1 C6orf26 and AIF1
aVariants located in exonic regions only.
208 Human MHC Resequencing [Vol. 18,ligand for the NKG2D type II receptor. Binding of the
ligand activates the cytolytic response of natural killer
(NK) cells, CD8 alpha/beta T cells and gamma/delta T
cells, which express the receptor. This protein is stress
induced and is similar to MHC class I molecules. MICB
seems to have no role in antigen presentation, but
acts as a stress-induced self-antigen, a ligand for
KLRK1/NKG2D receptor, that is recognized by
gamma/delta T cells.
23,24
Ubiquitin-binding domains of the gene ubiquitin D
(UBD) are modular elements that bind non-covalently
to the protein modiﬁer ubiquitin. The sequence
context of UBDs and the conformational changes
that follow their binding to ubiquitin also contribute
to ubiquitin signalling and can therefore inﬂuence
ubiquitins functions in HLA molecule expression and
antigen presentation as well as dendritic cell
activation.
25
PSMB9 is different at three exonic positions.
A recent publication with a rat cardiac allograft
model has shown that immunoproteasome beta
subunit 10 was found to be speciﬁcally increased in
the graft and blood samples during chronic active
antibody-mediated rejection. Using this model, they
found that administration of the proteasome
inhibitor, bortezomib, delayed acute rejection and
attenuated the humoral response in both the acute
phase and established state of this syndrome in a
dose-dependent manner.
26
3.9 Genome-wide SNP analysis
The analysis of the SNPs located inside MHC by next
generation sequencing was complemented by whole
genome SNP analysis. In total, we compared 885 576
SNPs equally well distributed throughout the genome
observing that 62% (551 954) are shared between
donor and recipient outside the MHC, whereas 86%
(1365) are shared inside the MHC, reﬂecting the
higher linkage equilibrium of MHC localized loci
(Fig. 4). Taken into account that great variance exists
between persons as well as demographic groups, this
analysis can for the time being only be an estimate as
a consequence of missing data on an individuals’
variant level. Validation results from Affymetrix-SNP
datawithintheMHCregionshow93.38%concordance
withthenextgenerationsequencedata.Onthebasisof
more individuals’ sequence availability for MHC, the
data for SNP design will improve accordingly, but
whether itwill ever meetthepowerofdirect resequen-
cing is an unanswered question.
5. Conclusions
Rapidly evolving next generation sequencing tech-
nologies have reduced the hands on time and the
cost per base compared with Sanger sequencing and
are beginning to spread into disease prog- and diag-
nostics. New methodological applications, for inten-
sive characterization of donor and recipient, minor
and major histocompatibility antigens or other bio-
marker candidates affecting transplant outcome can
clearly help select the best-matched donor by extend-
ing the list of genes screened. The list of candidate
genes affecting GVHD induction and maintenance is
long and the mechanisms are likely to be diverse.
The data presented here demonstrate the utility of
targeted sequence capture and massive parallel
sequencing in detailed characterization of the
genetic diversity of the donor and the recipient MHC
repertoire. Such a wealth of information derived
from such studies will lead to extended personalized
genomic knowledge on individual MHC structures,
SNPs disease associations, drug efﬁcacy information,
minor histocompatibility antigen polymorphisms or
T-cell epitope formation, all crucial for further
Figure 4. Summary of SNP array results for donor and recipient inside and outside MHC. Analysis of Affymetrix microarray HGW SNP 6.0
data for SNP density and signal intensities. (A) The slope of the graph represents the cumulative number of variant SNPs (x ¼ number of
SNPs; y ¼ number of variant SNPs). Inset MHC region (Chr.6: 29 000 000–34 999 000 only) and with unrelated not HLA matched
control sample (inset blue). (B) Correlation of signal intensities for concordant and variant SNP’s inside and outside the MHC region.
Taken together, showing that HLA matching in contrast to an unrelated and HLA unmatched control sample signiﬁcantly reduces
the variant SNP density in MHC regions (R ¼ 0.892 versus R ¼ 0.704; z ¼ 6.76) and not in non-MHC regions (R ¼ 0.801 versus R ¼
0.740; z ¼ 234.53).
No. 4] J. Pro ¨ll et al. 209improvement of donor selection and T cell transfer
strategies. Ongoing developments in targeted
sequence capture in solution and the scheduled
1 kb read length in 454’s pyrosequencing technology
together with supplemental analysis for haplotype
structures will increase the impact of that type of
analysis in the ﬁeld of transplant medicine.
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